REFERENCES
- Bonder A. L., Zanotto C. E., Piacentini G., Miglioranzi P., Richelli C., Sette L. Efficacy and duration of action of oral procaterol in asthmatic children after single administration of different dosages. J. Asthma 1990; 27: 21–30
- Chopra R., Podczeck F., Newton J. M., Alderborn G. The influence of pellet shape and film coating on the filling of pellets into hard shell capsules. Eur. J. Pharm. Biopharm. 2002; 53: 327–333
- Christensen F. N., Bertelsen P. Qualitative description of the wurster-based fluid-bed coating process. Drug Dev. Ind. Pharm 1997; 23: 451–463
- Cole G., Hogan J., Aulton M. Pharmaceutical coating technology. Coating Pans and Coating Columns, G. Cole. Informa UK Ltd, London 1995; 203–232
- Eldon M. A., Blake D. S., Coon M. J., Nordblom G. D., Sedman A. J., Colburn W. A. Clinical pharmacokinetics of procaterol: dose proportionality after administration of single oral doses. Biopharmac. Drug Disp 1992; 13: 663–669
- El-Mahdi I. M., Deasy P. B. Tableting of coated ketoprofen pellets. J. Microencapsulation 2000; 17: 133–144
- Folco G. C., Passoni E., Vigano T., Daffonchio L., Rossoni G., Brunelli G., Berti F. New pharmacological aspects of the bronchodilating activity of procaterol. Pharmacol. Res. Comm 1983; 15: 909–921
- Gibaldi M. Biopharmaceutics and Clinical Pharmacokinetics 3rd. Informa UK Ltd, Philadelphia 1984
- Hausman D. S. Comparison of low shear, high shear, and fluid bed granulation during low dose tablet process development. Drug Dev. Ind. Pharm 2004; 30: 259–266
- Kemp J. P., Welch M. J., Meltzer E. O., Orgel H. A. Therapeutic efficacy and equivalence of tablet and syrup formulations of procaterol hydrochloride in childhood asthma. Ann. Allergy 1985; 55: 588–592
- Kokubo, H., Obara, S., & Nishiyama, Y. (1998) Application of extremely low viscosity methylcellulose (MC) for pellet film coating. 46, 1803–1806.
- Krogars K., Heinamaki J., Vesalahti J., Marvola M., Antikainen O., Yliruusi J. Extrusion-spheronization of pH-sensitive polymeric matrix pellets for possible colonic drug delivery. Int. J. Pharm 2000; 199: 187–194
- Rowe R. C. Defects in Aqueous Film-Coated Tablets. Aqueous Polymeric Coatings for Pharmaceutical Dosage Forms, J. W. McGinity. Informa UK Ltd, New York 1997; 419–440
- Saitoh Y., Hosokawa T., Igawa T., Irie Y. Effect of a selective β2-adrenoceptor agonist, procaterol, on tissue cyclic AMP level. Biochem. Pharmacol. 1979; 28: 1319–1322
- Shah V. P., Tsong Y., Sathe P., Liu J. P. In vitro dissolution profile comparison-statistics and analysis of the similarity factor, f2. Pharm. Res. 1998; 15: 889–896
- Wright D. S., Pachla L. A., Gibson D. M., Jordan R. A. Sensitive high-preformance liquid chromatographic method for procaterol in human urine. J. Chromatogr. 1987; 417: 223–228
- Yalkowsky S. H., Bolton S. Particle size and content uniformity. Pharm. Res. 1990; 7: 962–966
- Yamashita S., Takai M., Yabuuchi Y. Actions of procaterol (OPC-2009), a new β2-adrenoceptor stimulant, on pulmonary resistance, contractions of the soleus muscle, and cardiovascular system of the anaesthetized cat. J. Pharm. Pharmac. 1978; 30: 273–279
- Young C. R., Koleng J. J., McGinity J. W. Production of spherical pellets by a hot-melt extrusion and spheronization process. Int. J. Pharm. 2002; 242: 87–92
- Yu T. W., Chen R. R. L., Gau C. S. A novel liquid chromatography/mass/mass spectrometry system to determine procaterol levels in human plasma. J. Food & Drug Anal 2005; 13(4)312–318